… for mCRC patients treated with first-line chemotherapy plus bevacizumab. PFS was defined
as the time from the beginning of the … Correlation of bevacizumabinduce hypertension and …

… Fisher’s exact test was used to assess the correlation between DCR, PFS, OS, and tumor …
used to estimate the correlation between PFS, OS rates, and clinic-pathological variables at 95…

… and an anti-EGFR agent with chemotherapy should not be used in patients treated in first
line with mCRC. Ongoing studies continue to evaluate the role of this strategy in more …

… tumors of 53 metastatic colorectal cancer patients receiving chemotherapy in combination
with first line bevacizumab. … correlates with response to neoadjuvant bevacizumab followed by …

… , or bevacizumab discontinuation if occurring during treatment. … % of patients developed
new-onset arterial hypertension that … Hypertension is commonly seen to develop in BVZ-treated …

… clinical outcomes when adding bevacizumab to chemotherapy for patients with metastatic
colorectal cancer (… effect of bevacizumab exclusively in the first‐line treatment setting, where …

… tumour RAS status ahead of bevacizumab treatment is less clear [3… or FOLFIRI for the first-line
treatment of patients with RAS WT (no … and bevacizumab treatment in the first-line setting. …

… the clinical setting and the results of two non-randomized observational cohort studies (BRiTE
and ARIES) showed a correlation between the use of bevacizumab beyond progression to …

… first-line management of mCRC in most developed countries [4, 7–9]. However, there are
major clinical implications with the use of bevacizumab… containing bevacizumab was correlated …

… of Bevacizumab plus first-line chemotherapy in 1914 mCRC … 1631 patients treated with
Bevacizumab for advanced cancers, … positively associated with Bevacizumab-induced HTN [63]. …